# Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies

> **NCT00894894** · PHASE1 · COMPLETED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** MP-470
- **DRUG:** amuvatinib (MP-470)

## Key facts

- **NCT ID:** NCT00894894
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00894894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00894894, "Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00894894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*